Abstracts tagged "neurology"

Abstract Number: 1475 • ACR Convergence 2022
Epidemiology of Acute Ischemic Stroke in Patients with Systemic Lupus Erythematosus
Uzair Khan¹, Izza Bazigh², Achint Patel³, Aaparna Singh³, Neha Ghalib³, Ghazi Farman⁴, Salman Muddassir³, Farrukh Zaidi⁵, Sami Mughni³ and Adam Grunbaum⁶, ¹HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Odessa, FL, ²HCA Florida Oak Hill Hospital, Spring Hill, FL, ³HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Spring Hill, FL, ⁴Rehman Medical College, Spring Hill, FL, ⁵HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Port Richey, FL, ⁶Gulf Coast Rheumatology, Trinity, FL
Background/Purpose: Vascular events, including cerebrovascular accidents (CVA) occur earlier and more frequently in patients with Systemic Lupus Erythematosus (SLE) compared with healthy individuals. Several studies…
Abstract Number: 1479 • ACR Convergence 2022
Association of Neuromyelitis Optica and Systemic Lupus Erythematosus: Analysis of National Inpatient Sample 
Faria Sami and Shilpa Arora, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Neuromyelitis Optica (NMO), also known as Devic's disease, is a rare inflammatory demyelinating disorder causing myelitis and optic neuritis. While there have been reports…
Abstract Number: 1556 • ACR Convergence 2022
Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease
Alba Herrero-Morant¹, José Luis Martín-Varillas², Santos Castañeda³, Olga Maiz⁴, Julio Sánchez-Martín⁵, Norberto Ortego⁶, Enrique Raya⁷, Águeda Prior-Español⁸, Clara Moriano⁹, Rafael Melero¹⁰, Genaro Graña-Gil¹¹, Ana Urruticoechea¹², Angel Ramos¹³, Marta Loredo-Martínez¹⁴, Eva Salgado-Pérez¹⁵, Francisca Sivera¹⁶, Ignacio Torre¹⁷, F. Javier Narváez¹⁸, Jose Luis Andreu¹⁹, Olga Martinez²⁰, Ricardo Gómez-de la Torre²¹, Sabela Fernandez-Aguado²², Susana Romero Yuste²³, iñigo Gonzalez-Mazon⁵, Carmen Alvarez Reguera⁵, David Martínez-López⁵, José Luis Hernández⁵, Miguel Ángel González-Gay²⁴ and Ricardo Blanco²⁵, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital de Laredo, Laredo, Cantabria, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Hospital Universitario de Donostia, San Sebastián, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Medicine Department, Universidad de Granada, Granada, Spain, ⁷Hospital San Cecilio, Granada, Spain, ⁸Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁹Complejo Asistencial Universitario de León, León, Spain, ¹⁰Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ¹¹Hospital Universitario de A Coruña, A Coruña, Spain, ¹²Hospital Can Misses, Ibiza, Spain, ¹³Complejo Hospitalario de Soria, Soria, Spain, ¹⁴Hospital Clínico Lozano Blesa, Zaragoza, Spain, ¹⁵Complejo Hospitalario Universitario de Ourense, Santiago de Composte, Spain, ¹⁶Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁷Hospital de Basurto, Basurto, Spain, ¹⁸Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²⁰Hospital Clínico Universitario de Salamanca, Zamora, Spain, ²¹Hospital Universitario Central de Asturias, Oviedo, Spain, ²²Hospital Universitario de Cabueñes, Gijon, Spain, ²³Complexo Hospitalario Universitario, Pontevedra, Spain, ²⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ²⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behcet's disease. NBD can be classified as a) primary neural parenchymal lesions, also…
Abstract Number: 1558 • ACR Convergence 2022
Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain
Alba Herrero-Morant¹, Carmen Alvarez Reguera², Lara Sánchez-Bilbao², David Martínez-López², guillermo Suárez-Amorin², Raúl fernández-ramón², José Luis Martín-Varillas³, Cristina Mata⁴, Miguel Ángel González-Gay⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital de Laredo, Laredo, Cantabria, Spain, ⁴Hospital Laredo, Santander, Spain, ⁵Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behçet's disease (BD) may present with different clinical phenotypes. Ocular and Neurobehçet's Disease (NBD) are severe complications. Data on NBD epidemiology, clinical phenotype and…
Abstract Number: 1844 • ACR Convergence 2022
Biological Therapy in Neurosarcoidosis: Study of 30 Patients from a Series of 234 Systemic Sarcoidosis from a University Hospital
Alba Herrero-Morant¹, David Martínez-López², Lara Sánchez-Bilbao², iñigo Gonzalez-Mazon², José Luis Martín-Varillas³, Raúl fernández-ramón², Carmen Alvarez Reguera², Miguel Ángel González-Gay⁴ and Ricardo Blanco⁵, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital de Laredo, Laredo, Cantabria, Spain, ⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Neurosarcoidosis (NS) is a severe complication of sarcoidosis. NS may be classified according to several subtypes. Data on therapy, including biological therapy (BT) is…
Abstract Number: 0651 • ACR Convergence 2021
Diagnostic Approach to Identifying Small Fiber Neuropathy in Patients with Sarcoidosis
Bassel Bou Dargham¹, Nima Madanchi², Kelsey Satkowiak¹, Huzaefah Syed¹ and Kelly Gwathmey³, ¹Virginia Commonwealth University Medical Center, RICHMOND, VA, ²Virginia CommonHealth University Medical Center, Richmond, VA, ³Virginia Commonwealth University Health system, Richmond, VA
Background/Purpose: Sarcoidosis is a multisystem granulomatous disease that can affect the nervous system in about 5% of patients. Sarcoidosis associated small fiber neuropathy (SSFN) presents…
Abstract Number: 0703 • ACR Convergence 2021
CD8 Positron Emission Tomography (PET/CT) Imaging with 89Zr-Df-IAB22M2C in Patients with Inclusion Body Myositis
Colin Quinn¹, Kelsey Moulton¹, Ron Korn², William Le³, Niti Goel⁴, Michael Farwell⁵ and Steven Greenberg⁶, ¹Department of Neurology, University of Pennsylvania, Philadelphia, PA, ²ImaginAb, Inglewood, CA, ³ImaginAb, Inc, Inglewood, CA, ⁴Abcuro, Inc., Newton,, MA, ⁵Department of Radiology, University of Pennsylvania, Philadelphia, PA, ⁶Brigham and Women's Hospital Department of Neurology, Boston, MA
Background/Purpose: Inclusion body myositis (IBM) is a slowly progressive autoimmune skeletal muscle disease for which no effective pharmacological therapy is available. A prominent feature of…
Abstract Number: 0712 • ACR Convergence 2021
Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?
Hortense Chassepot¹, Lotta Plomp², Dimitri Psimaras³, Thierry Maisonobe³, Sarah Leonard Louis⁴, Isabelle Plu⁴, Mehdi Touat³, Celine Anquetil⁵, Nadege Wesner⁵, Nicolas Champtiaux⁵, Aude Rigolet⁵, Sophie Demeret³, Nicolas Weiss³, Baptiste Abbar⁶, Marie-Claire Bretagne⁷, Bruno Pinna⁷, Capucine Morelot⁸, Martin Dres⁸, Thomas Similowski⁸, Stephane Ederhy⁹, Joe-Elie Salem⁷, Olivier Benveniste⁵ and Yves Allenbach⁵, ¹Universite de Picardie Jules Verne UPJV - Amiens Picardie Hospital, Department of Clinical Immunology and Internal Medicine, Fourqueux, France, ²Amsterdam University Medical Center (AUMC), Amsterdam, Netherlands, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France, ⁴Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, Paris, France, ⁵Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ⁶Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Oncology, Paris, France, ⁷Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, Paris, France, ⁸Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pneumology - R3S, Paris, France, ⁹Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Cardiology, Paris, France
Background/Purpose: Immune checkpoint inhibitor (ICI)-related adverse events (irAE) recently emerged as new diseases in the field of auto-immunity. Among them, ICI-related myotoxicity has the highest…
Abstract Number: 1096 • ACR Convergence 2021
CSF-specific CD8 T Cell Clonal Expansion in Neurosarcoidosis
Michael Paley¹, Brandi Baker², Steven Dunham³, Nicole Linskey³, Elisha Roberson³, David Clifford³ and Wayne Yokoyama³, ¹Washington University in St. Louis, Olivette, MO, ²Washington University in St. Louis, St. Louis, MO, ³Washington University School of Medicine, St. Louis, MO
Background/Purpose: Neuroinflammation is a severe manifestation of the systemic inflammatory disorders. Sarcoidosis, which leads to neurologic disease in 5-10 % of cases, has traditionally been…
Abstract Number: 1114 • ACR Convergence 2021
Pachymeningitis: The Mayo Clinic Experience
Emily Gilbert¹, Mina Al-Awqati², Tina Gunderson³ and Florentina Berianu¹, ¹Mayo Clinic, Jacksonville, FL, ²University of Illinois, Chicago, IL, ³Mayo Clinic, Rochester, MN
Background/Purpose: Pachymeningitis is a rare disorder defined by localized or generalized inflammatory thickening of the dura. It can be associated with infections, malignancy, autoimmune disorders,…
Abstract Number: 1883 • ACR Convergence 2021
Neuro-Behcet’s Disease: 20 Years Single Center Experience of Cyclophosphamide for Induction of Remission
Pablo Vinicius da Fonseca, Henrique Ayres Mayrink Giardini,, Célio Roberto Gonçalves and Leandro Lara do Prado, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Behçet's disease (BD) is a systemic vasculitis. Neurological involvement, also known as Neuro-Behçet's disease (NBD), leads to great morbimortality. Diagnosis is challenging, since clinical…
Abstract Number: 1885 • ACR Convergence 2021
Biological Therapy in Refractory Neurobehçet’s Disease. Multicenter Study of 42 Patients
Alba Herrero-Morant¹, José Luis Martin-Varillas², Vanesa Calvo-Río³, Santos Castañeda⁴, Olga Maíz⁵, Ana Blanco⁶, Julio Sánchez⁷, Norberto Ortego⁸, Enrique Raya⁹, Anahy Maria Brandy-Garcia¹⁰, Alejandro Olive-Marques¹¹, Agueda Prior-Español¹², Clara Moriano¹³, Elvira Díez¹⁴, Rafael Melero¹⁵, Jenaro Enrique Grana Gil¹⁶, Álvaro Seijas-López¹⁷, Ana Urruticoechea-Arana¹⁸, Ángel Ramos-Calvo¹⁹, Concepcion Delgado-Beltran²⁰, Marta Loredo-Martinez²⁰, Eva Salgado²¹, Francisca Sivera²², Ignacio Torre²³, Javier Narvaez²⁴, Jose Luis Andreu²⁵, Olga Martinez²⁶, Ricardo Gómez de la Torre²⁷, Sabela Fernandez-Aguado²⁸, Susana Romero-Yuste²⁹, Gerard Espinosa³⁰, Miguel Ángel gonzalez-Gay³¹ and Ricardo Blanco³, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Sierrallana, Torrelavega, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Hospital Universitario de Donostia, San Sebastián, Spain, ⁶Hospital Universitario de Donostia, San Sebastián, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Medicine Department, Universidad de Granada, Granada, Spain, ⁹Hospital San Cecilio, Granada, Spain, ¹⁰Hospital Germans Trias i Pujol, Badalona, Spain, ¹¹Rheumatology Service. Hospital Germans Trias i Pujol, Barcelona, Spain, ¹²Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Spain, ¹³Hospital Universitario de León, León, Spain, ¹⁴Hospital de León, León, Spain, ¹⁵Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ¹⁶Hospital Universitario de A Coruña, A Corua, Spain, ¹⁷Hospital Universitario de A Coruña, A Coruña, Spain, ¹⁸H. Can Misses, Elvissa, Spain, ¹⁹Complejo Hospitalario de Soria, Soria, Spain, ²⁰Hospital Clínico Lozano Blesa, Zaragoza, Spain, ²¹Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ²²Hospital Universitario de Elda, Alicante, Spain, ²³Hospital Universitario de Basurto, Bilbao, Spain, ²⁴Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶H. Salamanca, Zamora, Spain, ²⁷H. Asturias, Oviedo, Spain, ²⁸Hospital Universitario de Cabueñes, Gijón, Spain, ²⁹Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁰Hospital Clinic, Barcelona, Spain, ³¹Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Neurobehçet’s disease (NBD) is a severe complication of Behcet's disease (BD). Despite well-established therapies, with glucocorticoids and conventional immunosuppressants (cIS) a significant proportion of…
Abstract Number: 0123 • ACR Convergence 2021
Vestibulocortical Stimulation with Caloric Irrigation Reduces Pain and Improves Subjective Well-Being in Fibromyalgia: An Open-Label Pilot Trial
Michael Kaplan¹, Celine Zhou¹, Emily Carroll¹, Alan Weinberg², Daniel Clauw³, Trung Thanh Ngo⁴ and Ioannis Tassiulas⁵, ¹The Mount Sinai Hospital, Manhattan, NY, ²The Mount Sinai Hospital, New York, NY, ³University of Michigan, Ann Arbor, MI, ⁴University of Queensland & Translational Research Institute, Woolloongabba, Australia, ⁵Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Safe and effective therapies for fibromyalgia (FM) remain a major unmet clinical need. Vestibulocortical stimulation (VCS) via caloric irrigation is a safe, inexpensive, non-invasive…
Abstract Number: 0417 • ACR Convergence 2021
Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Rula Hajj-Ali¹, Robert Butler², Carol Langford³, Leonard Calabrese², David Cuthbertson⁴, Nader Khalidi⁵, CURRY LEE MD KOENING⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih⁷, Kenneth Warrington¹³ and Peter Merkel⁷, ¹Cleveland Clinic, Hunting Valley, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Moreland Hills, OH, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³Mayo Clinic, Rochester, Minnesota
Background/Purpose: The prevalence of neurologic involvement (NI) in ANCA-associated vasculitis (AAV), especially central nervous system (CNS) involvement, is not well characterized. This project aimed to…
Abstract Number: 0431 • ACR Convergence 2021
Clinical Characteristics and Outcomes of ANCA-Associated and Non Immune-Mediated Hypertrophic Pachymeningitis: A Comparative Study
Eduardo Martin-Nares, Lilian Guadalupe Cano Cruz and Andrea Hinojosa-Azaola, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Hypertrophic pachymeningitis (HP) is an infrequent manifestation in autoimmune and non-autoimmune conditions. The differences in clinical characteristics and outcomes of ANCA-associated and non-immune-mediated HP…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].